title: Managing HIV. Part 4: Primary therapy. 4.2 Immune-based therapy for HIV infection.
abstract: Immune-based therapy is in its infancy and to date no therapies are licensed in Australia. A number of the reagents are reaching phase III clinical trials and may be available within two years. Patient and physician interest is high because antiretroviral agents have not as yet had a significant impact on survival.
authors.affiliation: Department of Immunopathology, Institute for Clinical Pathology and Medical Research, Westmead Hospital, Sydney, NSW Australia.
authors.forename: E M
authors.initials: EM
authors.lastname: Benson
authors.forename: M A
authors.initials: MA
authors.lastname: French
authors.forename: R T
authors.initials: RT
authors.lastname: Schooley
mesh_terms: D000276:Adjuvants, Immunologic / Q000627:therapeutic use; D016207:Cytokines / Q000627:therapeutic use; D015658:HIV Infections / Q000628:therapy*; D006801:Humans; D007136:Immunoglobulins / Q000627:therapeutic use; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D007167:Immunotherapy / Q000379:methods*
chemical_list: D000276:Adjuvants, Immunologic; D016207:Cytokines; D007136:Immunoglobulins; D007166:Immunosuppressive Agents